Drug intelligence / Profile preview

kangfuxin

Development stage
Approved
Lead developer
Sichuan Gooddoctor Panxi Pharmaceutical
Administration
Oral, Topical, Rectal
01

Overview

Kangfuxin is a traditional Chinese medicine approved by China's National Medical Products Administration (NMPA) and is composed solely of an ethanol extract from the dried bodies of the American cockroach, *Periplaneta americana*. [1, 3, 5] It is developed and manufactured by companies such as Sichuan Good Doctor Pharmaceutical Group. The drug is primarily used for tissue repair and wound healing and is formulated as a liquid solution for oral, topical, or rectal administration. [2, 16] Clinical studies have investigated its use for various conditions, including radiotherapy-induced oral mucositis, gastric and duodenal ulcers, ulcerative colitis, burns, and other external wounds. [2, 4, 16] Its mechanism of action includes promoting blood circulation, accelerating granulation tissue growth, and reducing inflammation. [11, 14, 16] Scientific studies suggest that it protects the intestinal mucosal barrier and alleviates colitis by inhibiting the RIP1/RIP3/MLKL-mediated necroptosis pathway and the activation of the NF-κB and NLRP3 inflammasome signaling pathways, which reduces the production of pro-inflammatory cytokines.

Brand names
KangfuxinKangfuxin SolutionKangfuxin Ye康复新液
Other names
Kangfuxin liquidPeriplaneta americana extract
02

Targets

MLKL (Mixed lineage kinase domain-like protein)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)RELA (Nuclear Factor Kappa B Subunit p65)RIPK1 (Receptor-interacting serine/threonine-protein kinase 1)RIPK3

Beyond the preview

Go deeper on kangfuxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on kangfuxin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call